Biologic and Clinical Perspectives on Thyroid Cancer

Fagin, James A.; Wells, Samuel A.

doi:10.1056/nejmra1501993

Cited by 701 publications

(725 citation statements)

References 87 publications

(98 reference statements)

Supporting

Mentioning

698

Contrasting

Unclassified

Order By: Relevance

“…Anaplastic thyroid cancer also carries mutations in p53, TERT promoter, and phosphatidylinositol 3‐kinase, among others [7], [8]. However, limited data exist on immunotherapy, given the extreme virulence and genetic complexity of ATC.…”

Section: Molecular Tumor Boardmentioning

confidence: 99%

Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Molecular Tumor Boardmentioning

confidence: 99%

Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Over the past 40 years, the incidence of thyroid cancer has steadily escalated in many countries of the world (Fagin & Wells 2016, Howlader et al 2017, Siegel et al 2017. Thyroid cancers generally originate either from follicular or parafollicular C cells.…”

Section: Introductionmentioning

confidence: 99%

“…Differentiated thyroid cancer (DTC) comprises the common thyroid cancer types, PTC and FTC. Medullary thyroid cancer is derived from chief cells or parafollicular C cells which account for a minor portion of thyroid cancer (DeLellis et al 2004, Fagin & Wells 2016. Among these subtypes (PTC, FTC, PDTC and ATC) of thyroid cancers, PTC is the major form of thyroid cancer accounting for approximately more than 85% (Fagin & Wells 2016).…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNAs: emerging players in thyroid cancer pathogenesis

Murugan

Munirajan

Alzahrani

2018

Endocrine-Related Cancer

110

103

View full text Add to dashboard Cite

Thyroid cancer continues to be the most common malignancy of endocrine glands. The incidence of thyroid cancer has risen significantly over the past 4 decades and has emerged as a major health issue. In recent years, significant progress has been achieved in our understanding of the molecular mechanisms of thyroid carcinogenesis, resulting in significant diagnostic, prognostic and therapeutic implications; yet, it has not reached a satisfactory level. Identifying novel molecular therapeutic targets and molecules for diagnosis and prognosis is expected to advance the overall management of this common malignancy. Long noncoding RNAs (lncRNAs) are implicated in the regulation of various key cellular genes involved in cell differentiation, proliferation, cell cycle, apoptosis, migration and invasion mainly through modulation of gene expression. Recent studies have established that lncRNAs are deregulated in thyroid cancer. In this review, we discuss extensively the tumor-suppressive (for example, LINC00271, MEG3, NAMA, PTCSC1/2/3, etc.) and oncogenic (for example, ANRIL, FAL1, H19, PVT1, etc.) roles of various lncRNAs and their possible disease associations implicated in thyroid carcinogenesis. We briefly summarize the strategies and mechanisms of lncRNA-targeting agents. We also describe the potential role of lncRNAs as prospective novel therapeutic targets, and diagnostic and prognostic markers in thyroid cancer.

show abstract

“…Several histologic types of thyroid cancer have been identified, including follicular thyroid carcinoma, papillary thyroid carcinoma, and anaplastic thyroid carcinoma 2. Although the advance on surgery, chemotherapy, and radiation therapy has led to a favorable survival rate of thyroid cancer patients, the incidence of thyroid cancer has significantly increased worldwide over the past few decades 3, 4.…”

Section: Introductionmentioning

confidence: 99%

Identification of differential expressed lncRNAs in human thyroid cancer by a genome‐wide analyses

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Recently, a growing number of evidence has revealed that long noncoding RNAs (lncRNAs) act as key regulators in various cellular biologic processes, and dysregulation of lncRNAs involves in tumorigenesis and cancer progression. However, the expression pattern, clinical relevance, and biologic function of most lncRNAs in human thyroid cancer remain unclear. To identify more thyroid‐cancer‐associated lncRNAs, we analyzed the expression profile of lncRNAs in thyroid cancer tissues and adjacent normal or non‐tumor tissues using RNA sequencing data and gene microarray data from The Cancer Genome Atlas and Gene Expression Omnibus. Annotation and analyses of these data revealed that hundreds of lncRNAs are differentially expressed in thyroid cancer tissues when compared with normal tissues. By copy number variation analyses, we identified that some of those dysregulated lncRNAs genome locus are accompanied with the copy number amplification or deletion. Moreover, some lncRNAs expression levels are significantly associated with thyroid cancer patients overall or recurrence‐free survival time, such as RUNDC3A‐AS1, FOXD2‐AS1, PAX8‐AS1, and CRYM‐AS1. Furthermore, we validated an lncRNA termed LINC00704 in thyroid cancer cells by performing loss of function assays. Downregulation of LINC00704 could significantly impair thyroid cancer cells proliferation, colony formation, inhibit cell‐cycle progression and cell invasion, and induce cell apoptosis. Taken together, our findings reveal that lots of lncRNAs are dysregulated and may play critical roles in thyroid cancer, and this study could provide useful resource for identification and investigation of novel lncRNA candidates for thyroid cancer.

show abstract

Biologic and Clinical Perspectives on Thyroid Cancer

Cited by 701 publications

References 87 publications

Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer

Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer

Long noncoding RNAs: emerging players in thyroid cancer pathogenesis

Identification of differential expressed lncRNAs in human thyroid cancer by a genome‐wide analyses

Contact Info

Product

Resources

About